National Institutes of Health, a Component of the US Dept. of Health & Human Services

Provid Pharmaceuticals Inc.

Michael Currens

Robert H Shoemaker

Yves Pommier

John Cardellina

Dominic Scudiero

Christopher Self

Guangtao Zhang

David Waugh

Andrew Jobson

George Lountos

Charles Michael Cook

Louis E Henderson

Robert J Fisher

Alan Rein

Andrew Vargha Colasanti

Bruce Crise

Shizuko Sei

Andrew Stephen

Hang Yuan, Legal Representative

Andy Jobson

Sudhir Kondapaka

Karen Worthy

Andrew Colasanti

Charles M Cook

John Cardelina

Robert Shoemaker

Christopher R Self

A method of treating an Hepatitis C Virus infection in a patient, comprising providing a therapeutically effective amount, to a patient in need thereof, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: Gis a group of the formula or where n is 0, 1, 2, 3, or 4 and Het is a 5- or 6-membered heteroaryl group containing 1 to 4 heteroatoms independently chosen from N, O, and S, which Het is optionally substituted. 

Method of treating HCV infection with a small molecule CHK2 inhibitor

Described herein are Chk2-inhibitor compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.

Use of Chk2 kinase inhibitors for cancer treatment

Provided herein are Compounds having the following structure: 

Kinase inhibitors, compositions thereof, and methods of use therewith

The invention provides methods and pharmaceutical compositions for inhibiting viral replication, particularly retroviral replication. The methods comprise administration of stibonic acid or diphenyl compounds that disrupt viral nucleocapsid binding to nucleic acids.

Identification of anti-HIV compounds inhibiting virus assembly and binding of nucleocapsid protein to nucleic acid

Growing community of inventors

Frederick, MD, United States of America

Michael Currens